Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Achillion Pharmaceuticals, Inc. (NQ: ACHN)
7.580 USD  -0.060 (-0.79%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Achillion Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 Next >
GREENESTONE IMPLEMENTING 'BUILD & BUY' GROWTH STRATEGY TO CAPITALIZE ON HUGE OPPORTUNITY IN BEHAVIORAL TREATMENT
October 10, 2012
from Business Wire News Releases
Biotech Industry Looks to Benefit From New Act Designed to Promote R&D Joint Ventures
October 09, 2012
Five Star Equities Provides Stock Research on Achillion Pharmaceuticals and Celldex Therapeutics Read More
from Marketwired News Releases
GreeneStone Supports the Cause of Mental Health with Charitable Foundation
October 02, 2012
from Business Wire News Releases
GreeneStone Muskoka Once Again Featured on Intervention Canada
October 01, 2012
from Business Wire News Releases
Achillion Announces Positive Proof-of-Concept Data With ACH-3102
September 27, 2012
from GlobeNewswire News Releases
Achillion to Webcast September 27th Analyst Day
September 21, 2012
from GlobeNewswire News Releases
GreeneStone Addressing Eating Disorder Epidemic with Expanded Clinical Staff and Clinic Launch in Autumn 2012
September 20, 2012
from Business Wire News Releases
Today's Market Focus: Questcor, Regions Financial, Achillion, Deckers Outdoor, Yamana Gold, and NIKE
September 20, 2012
from PR Newswire
Active Stocks on Trader's Radar for 09/19/12- PZOO, ACHN, SRGE, CTRP
September 19, 2012
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by FinancialNewsMedia.com Read More
from Marketwired News Releases
Faster Approval Process Contributing to Biotech Industry's Success in 2012
September 13, 2012
The Paragon Report Provides Stock Research on Achillion Pharmaceuticals and Sunesis Pharmaceuticals Read More
from Marketwired News Releases
Achillion to Present at Four Upcoming Investor Conferences
August 31, 2012
from GlobeNewswire News Releases
Achillion to Raise $41.8 Million Through Registered Direct Offering
August 30, 2012
from GlobeNewswire News Releases
Patent Expirations for Major Pharmaceuticals Send Biotech Merger and Acquisition Activity to a Four-Year High
August 24, 2012
Five Star Equities Provides Stock Research on Achillion Pharmaceuticals and XOMA Read More
from Marketwired News Releases
Achillion to Present at the 2012 Wedbush Pacgrow Lifesciences Management Access Conference
August 10, 2012
from GlobeNewswire News Releases
Biotech Industry Soaring in 2012 -- ISIS Pharmaceuticals Surges on Strong Results
August 08, 2012
The Paragon Report Provides Stock Research on ISIS Pharmaceuticals and Achillion Pharmaceuticals Read More
from Marketwired News Releases
Achillion Reports Second Quarter and Six Month 2012 Financial Results
August 08, 2012
Conference Call to be Hosted Today at 10:00 a.m. EDT Read More
from GlobeNewswire News Releases
Achillion Announces Positive SVR4 Results From Phase 2 Study of Sovaprevir (Formerly ACH-1625) and Advancement of ACH-3102
August 07, 2012
from GlobeNewswire News Releases
Achillion to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012
July 31, 2012
Conference Call and Live Webcast Will Begin at 10:00 a.m. EDT on August 8, 2012 Read More
from GlobeNewswire News Releases
Booming Biotechnology Industry Continues to Impress Investors in 2012
July 12, 2012
Five Star Equities Provides Stock Research on Achillion and AVI BioPharma Read More
from Marketwired News Releases
Achillion to Present at the 2012 JMP Securities Healthcare Conference
July 10, 2012
from GlobeNewswire News Releases
Achillion to Present at 2012 Wells Fargo Securities Healthcare Conference
June 14, 2012
from GlobeNewswire News Releases
Achillion Appoints Kurt Graves to Its Board of Directors
June 11, 2012
from GlobeNewswire News Releases
Achillion Announces Resignation of Chief Medical Officer
June 06, 2012
from GlobeNewswire News Releases
Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C
May 21, 2012
Achieves Up to 3.73 log10 Reduction in Genotype 1 HCV RNA After Three Days of Treatment With Once-Daily 400 mg ACH-2684 in Phase 1b Study Read More
from GlobeNewswire News Releases
Achillion Announces Executive Promotion
May 18, 2012
from GlobeNewswire News Releases
ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
May 15, 2012
from GlobeNewswire News Releases
Achillion Reports First Quarter 2012 Financial Results
May 09, 2012
from GlobeNewswire News Releases
Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
May 09, 2012
Structurally Distinct NS5A Inhibitor Displays Potent Preclinical Activity Against Commonly Observed Resistant Variants Read More
from GlobeNewswire News Releases
Pharmaceutical Companies Look to Biotech Industry to Combat Losses from Expiring Patents
April 24, 2012
The Paragon Report Provides Stock Research on Achillion Pharmaceuticals and Keryx Biopharmaceuticals Read More
from Marketwired News Releases
Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C
April 23, 2012
from GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here